Evidence map›Paper›PMID 24621570›Full record

ArticlePloS one2014

A human integrin-α3 mutation confers major renal developmental defects.

Rachel Shukrun, Asaf Vivante, Oren Pleniceanu, Einav Vax, Yair Anikster, Benjamin Dekel, Danny Lotan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Rachel ShukrunPediatric Stem Cell Research Institute, Edmond and Lili Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Asaf VivantePediatric Stem Cell Research Institute, Edmond and Lili Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Oren PleniceanuPediatric Stem Cell Research Institute, Edmond and Lili Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Einav VaxPediatric Stem Cell Research Institute, Edmond and Lili Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yair AniksterSheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat Gan, Israel; Department of Pediatrics and Pediatric Nephrology, Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
Benjamin DekelPediatric Stem Cell Research Institute, Edmond and Lili Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat Gan, Israel; Department of Pediatrics and Pediatric Nephrology, Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Danny LotanPediatric Stem Cell Research Institute, Edmond and Lili Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sheba Centers for Regenerative Medicine and Cancer Research, Sheba Medical Center, Ramat Gan, Israel; Department of Pediatrics and Pediatric Nephrology, Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
Sheba Medical Center · ILEdmond and Lily Safra Children's Hospital · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of the mammalian kidney is a highly complex process dependent upon the interplay of various cell types, secreted morphogens, and the extra-cellular matrix (ECM). Although integrins are the most important receptors for ECM proteins and are ubiquitously expressed during kidney development, mice lacking expression of integrin α3 (Itga3) do not demonstrate a reduced number of nephrons, but mostly a disorganized GBM (glomerular basement membrane) leading to proteinuria. Thus, ITGA3 is considered mostly a passive GBM stabilizer and not an active player in nephrogenesis. Recently, mutations in the human ITGA3 were shown to cause congenital nephrotic syndrome, epidermolysis bullosa and interstitial lung disease, otherwise termed NEP syndrome (Nephrotic syndrome, Epidermolysis bullosa and Pulmonary disease). Herein, we performed histological and molecular analysis on the kidneys of a single patient from the initial cohort harboring an ITGA3 mutation, to illuminate the role of ITGA3 in human renal development. We show the patient to harbor a unique phenotype at birth, including severe unilateral renal hypodysplasia. Interrogation of global gene expression in the hypodysplastic kidney versus three controls (fetal, child and adult kidneys) revealed perturbed expression in several renal developmental pathways implicated in hypodysplasia, including the Wnt, BMP (bone morphogenetic protein) and TGF (transforming growth factor) pathways. Moreover, the affected kidney showed upregulation of early embryonic genes (e.g. OCT4 and PAX8) concomitant with downregulated kidney differentiation markers, implying a defect in proper renal differentiation. In conclusion, we show for the first time that ITGA3 is not merely a passive anchor for renal ECM proteins, as predicted by mouse models. Instead, our results may suggest it plays a central role in the interplay of cells, morphogens and ECM, required for proper nephrogenesis, thus adding ITGA3 to the list of CAKUT (congenital anomalies of the kidney and urinary tract)-causing genes.

Indexed as

MutationAdultAnimalsEpidermolysis BullosaGene Expression Regulation, DevelopmentalHumansIntegrin alpha3KidneyLung DiseasesMiceNephrotic SyndromePhenotypeProtein TransportIntegrin alpha3

Identifiers

PMID24621570
PMCPMC3951280
OpenAlexW2014059914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.